Loading patent…
AssigneeNovo Nordisk A/S
InventorsIda Hilden, Jes Thorn Clausen, Lars Christian Petersen, Brit Binow Soerensen, Helle Heibroch Petersen, Anders Svensson
Estimating the term…
The invention relates to antibodies that are capable of specifically binding tissue factor pathway inhibitor (TFPI), neutralising free TFPI and reducing the clotting time of blood. Furthermore, the invention relates to polynucleotides that encode such antibodies and to cells that comprise the polynucleotides or that express the antibodies of the invention. Such antibodies have utility in the treatment of subjects with a coagulopathy, alone as well as in combination with a second agent.
An antibody that is capable of specifically binding to an epitope on the C-terminal of full length TFPI, wherein said epitope comprises an amino acid residue selected from the group consisting of Tyr23, Asn24, Ser25, Va126, Ile27, Gly28, Lys29, Arg31, Lys48, Gln49, Leu52 and Lys56 of SEQ ID NO:
Dependencies are inferred from the claim text.